Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

TXMD

TherapeuticsMD (TXMD)

TherapeuticsMD Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:TXMD
FechaHoraFuenteTítuloSímboloCompañía
10/05/202415:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TXMDTherapeuticsMD Inc
10/05/202415:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TXMDTherapeuticsMD Inc
10/05/202415:05Business WireTherapeuticsMD Announces First Quarter 2024 Financial ResultsNASDAQ:TXMDTherapeuticsMD Inc
29/03/202415:00Business WireTherapeuticsMD Announces Full Year 2023 Financial ResultsNASDAQ:TXMDTherapeuticsMD Inc
07/12/202315:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TXMDTherapeuticsMD Inc
06/12/202310:36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TXMDTherapeuticsMD Inc
17/11/202308:28Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:TXMDTherapeuticsMD Inc
14/11/202315:05Business WireTherapeuticsMD Announces Third Quarter 2023 Financial ResultsNASDAQ:TXMDTherapeuticsMD Inc
21/08/202315:20Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TXMDTherapeuticsMD Inc
14/08/202305:50Business WireTherapeuticsMD Announces Second Quarter 2023 Financial ResultsNASDAQ:TXMDTherapeuticsMD Inc
29/06/202316:22Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TXMDTherapeuticsMD Inc
28/06/202306:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TXMDTherapeuticsMD Inc
17/05/202316:05Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TXMDTherapeuticsMD Inc
17/05/202316:02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:TXMDTherapeuticsMD Inc
15/05/202315:38Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TXMDTherapeuticsMD Inc
15/05/202315:05Business WireTherapeuticsMD Announces First Quarter 2023 Financial ResultsNASDAQ:TXMDTherapeuticsMD Inc
04/05/202315:40Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:TXMDTherapeuticsMD Inc
01/05/202316:03Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:TXMDTherapeuticsMD Inc
07/04/202315:48Edgar (US Regulatory)Annual Report (10-k)NASDAQ:TXMDTherapeuticsMD Inc
07/04/202315:01Business WireTherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model TransitionNASDAQ:TXMDTherapeuticsMD Inc
31/03/202316:04Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:TXMDTherapeuticsMD Inc
13/02/202316:25Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:TXMDTherapeuticsMD Inc
06/01/202316:31Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:TXMDTherapeuticsMD Inc
03/01/202305:50Business WireTherapeuticsMD Completes Transaction to License Its Products to Mayne PharmaNASDAQ:TXMDTherapeuticsMD Inc
05/12/202201:39TipRanksTherapeuticsMD Inks Licensing Deal with Mayne PharmaNASDAQ:TXMDTherapeuticsMD Inc
04/12/202217:00Business WireTherapeuticsMD Announces Definitive Agreements to License its Products to Mayne PharmaNASDAQ:TXMDTherapeuticsMD Inc
14/11/202216:23Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:TXMDTherapeuticsMD Inc
14/11/202215:05Business WireTherapeuticsMD Announces Third Quarter 2022 Financial ResultsNASDAQ:TXMDTherapeuticsMD Inc
31/10/202205:50Business WireTherapeuticsMD Announces Additional $7 Million Private PlacementNASDAQ:TXMDTherapeuticsMD Inc
03/10/202205:50Business WireTherapeuticsMD Announces $7 Million Private PlacementNASDAQ:TXMDTherapeuticsMD Inc
 Showing the most relevant articles for your search:NASDAQ:TXMD